Table 1 Patient characteristics.
All patients | MTB therapy | Alternative therapy | P value | |
---|---|---|---|---|
Population (n, %) | 251 (100.00) | 47 (18.73) | 53 (21.12) | |
Mean age, standard deviation (years) | 59 ± 12.00 | 56.19 ± 14.04 | 55.87 ± 11.69 | 0.7608a |
Sex | 0.6854b | |||
Male (n, %) | 144 (57.37) | 29 (61.7) | 30 (56.7) | |
Female (n, %) | 107 (42.63) | 18 (38.30) | 23 (43.40) | |
ECOG PS at MTB | ||||
0 | 62 | 14 | 15 | >0.9999b |
1 | 55 | 13 | 13 | >0.9999b |
2 | 4 | 0 | 1 | >0.9999b |
5 | 8 | 0 | 0 | |
Recommendations (n, %) | 125 (49.80) | 47 (100.00) | 19 (35.85) | |
Evidence-level primary recommendation (n, %) | ||||
m1A | 30 (24.79) | 17 (36.17) | 1 (5.26) | 0.0133b |
m1B | 20 (16.53) | 8 (17.39) | 4 (21.05) | 0.735b |
m1C | 22 (18.18) | 7 (15.22) | 3 (15.79) | >0.9999b |
m2A | 18 (14.88) | 6 (12.77) | 5 (26.32) | 0.2753b |
m2B | 6 (4.96) | 1 (2.17) | 1 (5.26) | 0.5024b |
m2C | 13 (10.74) | 3 (6.38) | 2 (10.53) | 0.6208b |
m3 | 7 (5.79) | 2 (4.35) | 3 (15.79) | 0.1444b |
m4 | 5 (4.13) | 3 (6.52) | 0 (0.00) | 0.5498b |
Previous lines (median, range) | 2, 0–10 | 2, 0–6 | 2, 1–9 | 0.9166a |
Entity (n, %) | ||||
CRC | 36 (14.40) | 1 (2.13) | 6 (11.11) | 0.1182b |
iCCA | 33 (13.20) | 7 (14.89) | 5 (9.26) | 0.5395b |
PDAC | 18 (7.20) | 0 (0.00) | 3 (5.56) | 0.2461b |
Gastric Ca | 16 (6.40) | 5 (10.64) | 3 (5.56) | 0.4671b |
Sarcoma | 14 (5.60) | 6 (12.77) | 5 (9.26) | 0.7507b |
CUP | 13 (5.20) | 3 (6.38) | 4 (7.41) | >0.9999b |
pCCA | 10 (4.00) | 3 (6.38) | 0 (0.00) | 0.0973b |
Breast Ca | 10 (4.00) | 0 (0.00) | 3 (5.56) | 0.2461b |
eCCA | 9 (3.60) | 2 (4.26) | 3 (5.56) | >0.9999b |
Gallbladder Ca | 8 (3.20) | 2 (4.26) | 0 (0.00) | 0.2141b |
NSCLC | 8 (3.20) | 2 (4.26) | 1 (1.85) | 0.5964b |
Salivary gland Ca | 8 (3.20) | 3 (6.38) | 2 (3.70) | 0.6615b |
Urothelial Ca | 7 (2.80) | 1 (2.13) | 4 (7.41) | 0.3685b |
HNSCC | 6 (2.40) | 0 (0.00) | 3 (5.56) | 0.2461b |
HGSC | 5 (2.00) | 0 (0.00) | 2 (3.70) | 0.4974b |
Prostatic Ca | 5 (2.00) | 0 (0.00) | 2 (3.70) | 0.4974b |
Lymphoma | 4 (1.60) | 2 (4.26) | 1 (1.85) | 0.5964b |
Melanoma | 4 (1.60) | 1 (2.13) | 0 (0.00) | 0.4653b |
HCC | 4 (1.60) | 0 (0.00) | 1 (1.85) | >0.9999b |
NEC | 4 (1.60) | 1 (2.13) | 0 (0.00) | 0.4653b |
Oesophageal Ca | 4 (1.60) | 0 (0.00) | 2 (3.70) | 0.4974b |
Others (n ≤ 3 in all patients) | 24 (9.60) | 8 (17.02) | 4 (7.41) | 0.2169b |